Reversal of p15 hypermethylation and hematologic response of high-risk MDS patients after decitabine treatment
| Patient . | HypermC reversal . | Hematologic response . | DAC courses . | Survival (mo) . |
|---|---|---|---|---|
| 001 | Yes | Blast reduction, hematologic improvement | 6 | 27 |
| 002 | NM | Progression to AML | 4 | 7 |
| 003 | Yes | Complete remission | 5 | 16 |
| 004 | ND | Progressive cytopenia | 1 | 50 |
| 005 | Yes | Blast reduction | 4 | 15 |
| 006 | Yes | Hematologic improvement | 4 | 15 |
| 007 | Yes | Complete remission | 4 | 13 |
| 008 | No | Progression to AML | 1 | 11 |
| 009 | NM | Blast reduction, hematologic improvement | 4 | 31 |
| 010 | No | Progressive cytopenia | 1 | 10 |
| 011 | NM | Hematologic improvement | 2 | 38 |
| 012 | No | Progression to AML | 1 | 1 |
| 013 | Yes | Complete remission | 4 | 21 |
| 014 | ND | Toxic death | 1 | 2 |
| 015 | NM | Partial remission | 6 | 18 |
| 016 | Yes | Blast reduction, tril hematologic improvement | 6 | 44 |
| 017 | NM | Stable disease | 2 | 52 |
| 018 | Yes | Blast reduction | 2 | 5 |
| 019 | Yes | Blast reduction, hematologic improvement | 6 | 73 |
| 020 | NM | Blast reduction, hematologic improvement | 6 | 75 |
| 021 | NM | Progression to AML | 1 | 5 |
| 022 | ND | No decitabine treatment | — | 2 |
| 023 | ND | No decitabine treatment | — | 32+ |
| Patient . | HypermC reversal . | Hematologic response . | DAC courses . | Survival (mo) . |
|---|---|---|---|---|
| 001 | Yes | Blast reduction, hematologic improvement | 6 | 27 |
| 002 | NM | Progression to AML | 4 | 7 |
| 003 | Yes | Complete remission | 5 | 16 |
| 004 | ND | Progressive cytopenia | 1 | 50 |
| 005 | Yes | Blast reduction | 4 | 15 |
| 006 | Yes | Hematologic improvement | 4 | 15 |
| 007 | Yes | Complete remission | 4 | 13 |
| 008 | No | Progression to AML | 1 | 11 |
| 009 | NM | Blast reduction, hematologic improvement | 4 | 31 |
| 010 | No | Progressive cytopenia | 1 | 10 |
| 011 | NM | Hematologic improvement | 2 | 38 |
| 012 | No | Progression to AML | 1 | 1 |
| 013 | Yes | Complete remission | 4 | 21 |
| 014 | ND | Toxic death | 1 | 2 |
| 015 | NM | Partial remission | 6 | 18 |
| 016 | Yes | Blast reduction, tril hematologic improvement | 6 | 44 |
| 017 | NM | Stable disease | 2 | 52 |
| 018 | Yes | Blast reduction | 2 | 5 |
| 019 | Yes | Blast reduction, hematologic improvement | 6 | 73 |
| 020 | NM | Blast reduction, hematologic improvement | 6 | 75 |
| 021 | NM | Progression to AML | 1 | 5 |
| 022 | ND | No decitabine treatment | — | 2 |
| 023 | ND | No decitabine treatment | — | 32+ |
Reversal of p15 hypermethylation was defined as at least 25% reduction of methylation (relative to hypermethylation of more than 15% prior to treatment as given in Table 1). Thus, for the 7 patients with initial methylation of no more than 15%, reversal of hypermethylation was not measurable (NM). The total number of courses administered is given. Hematologic responses were defined as described in “Patients, materials, and methods.”12 Survival (in months) was from start of decitabine treatment (patients 001-021) or from diagnosis (patients 022, 023). For patient 001 at relapse and patient 018 during progression, p15 methylation was determined from peripheral blood MNCs because bone marrow MNCs were not available. ND indicates not done; —, no decitabine treatment; hematologic response not given because of early progression to AML (patient 022) and allogeneic transplantation as first line therapy (patient 023). Follow-up was until August 1, 2001.